Therapeutic perspective: starting an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in a diabetic patient

Abstract

There are extensive data confirming involvement of the renin-angiotensin system in microvascular and macrovascular complications of diabetes. Blockade of the system with angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) is regarded as the first-line approach to managing hypertension and end-organ protection in patients with diabetes. ACE inhibitors are still the preferred agents for most patients. Dose should be lower with renal impairment unless an agent which is not excreted by the kidneys is chosen. Dose should be titrated up to the maximum tolerated to optimize end-organ protection, and intermediate-acting agents should be given in a twice daily divided dose when higher doses are used. Electrolytes should be checked before commencing, 1-2 weeks later, and after each dose increment. A modest decrease in estimated glomerular filtration rate (eGFR) and increase in creatinine often occurs with ACE inhibitors or ARBs. The agents may need to be discontinued if eGFR decreases by >15%, if creatinine increases by >20%, or if hyperkalaemia develops. Cough occurs in 5-10% of patients taking ACE inhibitor, but not with ARBs. Angioedema is probably equally common with ACE inhibitor or ARBs. It is not widely appreciated that ACE inhibitors may precipitate hypoglycaemia in patients taking glucose-lowering medication. The combination of ACE inhibitor and ARB is not routinely indicated for either hypertension or end-organ protection. While patients should not be denied the undoubted benefits of these important classes of drugs, we should also guard against their indiscriminate use in patients with diabetes. We must also ensure that patients receive appropriate counselling and monitoring.

Keywords

diabetes hypertension renal impairment hyperkalaemia angiotensin-converting enzyme inhibitor angiotensin II receptor blocker cough angioedema

References

Black, H.R. , Davis, B. , Barzilay, J. , Nwachuku, C. , Baimbridge, C. , Marginean, H. et al. (2008) Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) . Diabetes Care 3: 353-360.

Braga, M.F. , Leiter, L.A. , Braga, M.F.B. and Leiter, L.A. ( 2009) Role of renin angiotensin system blockade in patients with diabetes mellitus . Am J Cardiol 104: 835-839.

Brown, N.J. , Byiers, S. , Carr, D. , Maldonado, M. , Warner, B.A. , Brown, N.J. et al. (2009) Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema . Hypertension 54: 516-523.

Cowan, B.R. , Young, A.A. , Anderson, C. , Doughty, R.N. , Krittayaphong, R. , Lonn, E. et al. (2009) Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]) . Am J Cardiol 104: 1484-1489.

Kintscher, U. and Kintscher, U. ( 2009) ONTARGET, TRANSCEND, and PRoFESS: New-onset diabetes, atrial fibrillation, and left ventricular hypertrophy . J Hypertens 27(Suppl 2): S36-S39.

Lefebvre, J. , Murphey, L.J. , Hartert, T.V. , Jiao Shan, R. , Simmons, W.H. , Brown, N.J. et al. (2002) Dipeptidyl peptidase IV activity in patients with ACE-inhibitor-associated angioedema . Hypertension 39: 460-464.

Mann, J.F. , Schmieder, R.E. , McQueen, M. , Dyal, L. , Schumacher, H. , Pogue, J. et al. (2008) Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multi-centre, randomised, double-blind, controlled trial . Lancet 372: 547-553.

Matfin, G. and Pratley, R.E. (2010) Advances in the treatment of prediabetes . Ther Adv Endocrinol Metab 1: 5-14.

Mauer, M. , Zinman, B. , Gardiner, R. , Suissa, S. , Sinaiko, A. , Strand, T. et al. (2009) Renal and retinal effects of enalapril and losartan in type 1 diabetes . New Engl J Med 361: 40-51.

10.

Morris, A.D. , Boyle, D.I. , McMahon, A.D. , Pearce, H. , Evans, J.M. , Newton, R.W. et al. (1997) ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes. DARTS/MEMO Collaboration . Diabetes Audit and Research in Tayside, Scotland. Medicines Monitoring Unit. Diabetes Care 20: 1363-1367.

11.

Oltmanns, K.M. , Deininger, E. , Wellhoener, P. , Schultes, B. , Kern, W. , Marx, E. et al. (2003) Influence of captopril on symptomatic and hormonal responses to hypoglycaemia in humans . Br J Clin Pharmacol 55: 347-353.

12.

Rave, K. , Flesch, S. , Kuhn-Velten, W.N. , Hompesch, B.C. , Heinemann, L. , Heise, T. et al. (2005) Enhancement of blood glucose lowering effect of a sulfonylurea when coadministered with an ACE inhibitor: Results of a glucose-clamp study . Diabetes Metab Res Rev 21: 459-464.

13.

Reboldi, G. , Gentile, G. , Angeli, F. , Verdecchia, P. , Reboldi, G. , Gentile, G. et al. (2009) Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: Update after recent clinical trials . Vasc Health Risk Manag 5: 411-427.

14.

Ricketti, A.J. , Cleri, D.J. , Ramos-Bonner, L.S. , Vernaleo, J.R. , Ricketti, A.J. , Cleri, D.J. et al. (2007) Hereditary angioedema presenting in late middle age after angiotensin-converting enzyme inhibitor treatment . Ann Allergy Asthma Immunol 98: 397-401.

15.

Sweileh, W.M. ( 2009) Target blood pressure attainment in diabetic hypertensive patients: Need for more diuretics? Int J Clin Pharmacol Ther 47: 434-438.